Role of Insulin Resistance in MAFLD
Open accessThe DOI matches its Crossref record; 195 of the 195 references it cites were found in a registry or an index.
Abstract
Many studies have reported that metabolic dysfunction is closely involved in the complex mechanism underlying the development of non-alcoholic fatty liver disease (NAFLD), which has prompted a movement to consider renaming NAFLD as metabolic dysfunction-associated fatty liver disease (MAFLD). Metabolic dysfunction in this context encompasses obesity, type 2 diabetes mellitus, hypertension, dyslipidemia, and metabolic syndrome, with insulin resistance as the common underlying pathophysiology. Imbalance between energy intake and expenditure results in insulin resistance in various tissues and alteration of the gut microbiota, resulting in fat accumulation in the liver. The role of genetics has also been revealed in hepatic fat accumulation and fibrosis. In the process of fat accumulation in the liver, intracellular damage as well as hepatic insulin resistance further potentiates inflammation, fibrosis, and carcinogenesis. Increased lipogenic substrate supply from other tissues, hepatic zonation of Irs1, and other factors, including ER stress, play crucial roles in increased hepatic de novo lipogenesis in MAFLD with hepatic insulin resistance. Herein, we provide an overview of the factors contributing to and the role of systemic and local insulin resistance in the development and progression of MAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Given that insulin resistance (IR) is widely recognized as the key underlying mechanism of metabolic syndrome, it is reasonable to consider IR as a central factor in the pathogenesis of MASLD, which can be viewed as the hepatic manifestation of metabolic syndrome [2,9-12].”
The cited source says what the claim attributes to it.
In the citing paper
“ChREBP, which is activated by carbohydrate uptake [9,34,78,83].”
The cited source says what the claim attributes to it.
In the citing paper
“Among the core insulin signaling mediators—including INSR, IRS1, IRS2, AKT1, and AKT2—IRS1 shows marked zonal expression, with approximately 2-fold higher levels in PV compared to PP regions [9,20].”
In the citing paper
“Many studies have shown that insulin- resistant conditions are accompanied by a substantial increase in MTP and apolipoprotein C3 (ApoCIII) expression and the production of hepatic VLDL-ApoB and VLDL-TG [2, 9,108,111].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
MORA, A., LIPINA, C., TRONCHE, F., SUTHERLAND, C., & ALESSI, D. R. (2005) · Biochemical Journal · doi:10.1042/bj20041782 · Cited by 92
RetractedSarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afy169 · Cited by 13,818
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin Resistance
Hotamisligil, G. S., Shargill, N. S., & Spiegelman, B. M. (1993) · Science · doi:10.1126/science.7678183 · Cited by 7,518
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239 · cited 2×
“, hepatocyte ballooning), with or without fibrosis [2].”
BackgroundMetabolic Endotoxemia Initiates Obesity and Insulin Resistance
Cani, P. D., Amar, J., Iglesias, M. A., Poggi, M., Knauf, C., Bastelica, D., Neyrinck, A. M., Fava, F., Tuohy, K. M., Chabo, C., et al. (2007) · Diabetes · doi:10.2337/db06-1491 · Cited by 6,638
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249 · cited 1×
“The global prevalence of NAFLD is estimated at 24%; the highest rates are reported from South America and the Middle East, followed by Asia, the USA, and Europe [3].”
BackgroundSREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Cited by
Items 301–400 of 506
Huneault, H. E., Lo, J. S., Bai, S., He, Z., McPhaul, M. J., Bril, F., Vos, M. B., & Cree‐Green, M. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000582 · Cited by 2
Yi, Y., Zc, M., Lin, C.-L., Yu, F., Dong, X.-M., Chen, Q.-Q., Xiao, T., & Zhang, J. (2024) · Physiological Research · doi:10.33549/physiolres.935297 · Cited by 2
Ramadan, F. H. J., Zahradka, P. C., & Taylor, C. G. (2026) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2026.110310 · Cited by 2
Roles of PPARα and PPARγ As Regulator of Free Fatty Acids in Nonalcoholic SteatohepatitisPreprint
Vu, H. T., Nguyen, V. D., & Matsubara, T. (2023) · Preprints.org · doi:10.20944/preprints202304.0356.v1 · Cited by 2
Wei, C., Wu, J., Zhang, C., Zhao, Y., Li, C., & Yang, X. (2023) · Exploration of Digestive Diseases · doi:10.37349/edd.2023.00031 · Cited by 2
Joubert, M. B. V., Oliva, M. E., Ingaramo, P. I., & D’Alessandro, M. E. (2025) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2025.112643 · Cited by 2
Yuan, H., Zhou, J., Zhang, T., Wu, X., Li, C., Yang, H.-J., Jeong, D., & Park, S. (2024) · Food Bioscience · doi:10.1016/j.fbio.2024.105720 · Cited by 2
Kushiro, K., Hirono, H., & Ohkoshi, S. (2025) · Sleep Medicine · doi:10.1016/j.sleep.2025.03.011 · Cited by 2
Zhang, Y., Wang, H., Wang, F., Guo, X., Zhao, M., Zhou, Z., Lin, X., Zheng, L., Wang, Y., Liu, C., et al. (2025) · Clinical Science · doi:10.1042/cs20257764 · Cited by 2
Hazaimeh, R. A., Shackelford, L. A., & Boateng, J. A. (2026) · Nutrients · doi:10.3390/nu18020181 · Cited by 2
Ciantar, J., Rajić, S., Kostiniuk, D., Raulamo, E., Kartiosuo, N., Lai, L., Mishra, P. P., Lyytikäinen, L., Kleber, M. E., Rovio, S., et al. (2026) · Clinical Epigenetics · doi:10.1186/s13148-025-02037-1 · Cited by 2
Prevalence and associated factors of MAFLD in adults with type 2 diabetes
He, Y., Xiao, F., Yi, B., & Lu, J. (2024) · PLOS Global Public Health · doi:10.1371/journal.pgph.0003572 · Cited by 2
Gao, M., Lin, C., Lǐ, Y., Li, L., Chen, X., Wang, J., Du, W., & Pan, Q. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01945-9 · Cited by 2
Li, Z., Jiang, S., Chen, R., Zhang, Z., Zheng, L., He, H., Feng, R., Du, S., Qiu, W., & Ye, W. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02704-5 · Cited by 2
Абатуров, А. Е., Березенко, В. С., & Нікуліна, А. О. (2025) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.21.2.2025.1522 · Cited by 2
Qin, L., Xiao, Q., & Deng, X. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s548513 · Cited by 2
Tawai, J., & Xiong, J. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01756-2 · Cited by 2
Tauriainen, M.-M., Lankinen, M. A., Hakumäki, J. M., Lahtinen, O., Husso, M., Ågren, J. J., Laakso, M., & Schwab, U. (2026) · European Journal of Nutrition · doi:10.1007/s00394-026-04031-6 · Cited by 2
Yilmaz, Y., Saeedian, B., Babajani, N., Ashtari, S., Ghorat, F., & Taheri, E. (2025) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2025.09.021 · Cited by 2
Wang, Y., Lu, Q., Ma, H., Huang, J., Zhang, B., Qin, Y., Feng, Z., & Jin, X. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1652271 · Cited by 2
Wang, S., Liu, X.-Y., He, J., Cui, Y., & Jia, A. (2025) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000003043 · Cited by 2
Xu, M., Wei, Y., Ye, L., Yan, B., Huang, S., Mo, Z., & Li, M. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1649466 · Cited by 2
Leszczynska, A., Alle, T., Kaufmann, B. K., Sung, H., Stoess, C., Reca, A., Kim, A. D., Kim, S., Tran, C., Oukoloff, K., et al. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00738 · Cited by 2
Jafari, E., Merat, S., Anoushiravani, A., Radmard, A. R., Roshandel, G., Sharafkhah, M., Khoshnia, M., Nateghi, A., Khuzani, A. S., Poustchi, H., et al. (2024) · Middle East Journal of Digestive Diseases · doi:10.34172/mejdd.2024.374 · Cited by 2
LncRNA Snhg3 Aggravates Hepatic Steatosis via PPARγ SignalingPreprint
Xie, X., Gao, M., Zhao, W. G., Li, C., Zhang, W., Yang, J., Zhang, Y., Chen, E., Guo, Y., Guo, Z., et al. (2024) · eLife · doi:10.7554/elife.96988.3 · Cited by 2
Kan, Y., Liu, Y., Huang, Y., Li, Z., Chang, J., Pang, W., Lin, W., & Hu, J. (2025) · Molecular Medicine Reports · doi:10.3892/mmr.2025.13682 · Cited by 2
Qi, W., Cao, X., Chen, Y., Chen, H., Li, X., Zhang, N., Liu, R., Wang, W., Zheng, S., Li, S., et al. (2025) · Portal hypertension & cirrhosis · doi:10.1002/poh2.70000 · Cited by 2
Zhen, T., Li, S., Pan, S., Yin, T., Wang, M., Guo, X.-J., Zhang, H., & Qin, R. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i13.104046 · Cited by 2
Song, B., Zhou, Y., Su, R., Wang, Y., Chen, S., & Chen, W. (2025) · European journal of medical research · doi:10.1186/s40001-025-03783-x · Cited by 2
Guo-qing, X., Song, Q., Jia, M., Yu, Y., Su, S., & Mao, J. (2025) · BMC Geriatrics · doi:10.1186/s12877-025-06882-w · Cited by 2
Chen, Q.-Q., Yi, Y., Ma, Z., Chen, Q.-L., Liu, Y.-F., Lin, C.-L., Wang, H., & Wu, Q. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.103806 · Cited by 2
Lauric Acid Improves Insulin Resistance State in Diet-induced Obese Mice
Wong, C.-H., Chew, C.-H., Fong, L. Y., & Choo, Q.-C. (2025) · Journal of Advanced Research in Micro and Nano Engieering · doi:10.37934/armne.35.1.4558 · Cited by 2
Zhang, F.-M., Zhao, H.-D., Qi, Z.-M., Chen, R., Liao, Z.-X., Xie, L., & Zheng, C. (2025) · Medicine · doi:10.1097/md.0000000000046085 · Cited by 2
Gorczyca-Głowacka, I., Nawacki, Ł., Kołomańska, M., Mazurkiewicz, R., Niżnik, M., Ratnicki, K., Czerniak, M., Myrcha, P., Bękarski, M., Rocha-Neves, J. P., et al. (2025) · Clinical and Experimental Hepatology · doi:10.5114/ceh.2025.151805 · Cited by 2
Triglyceride/HDL cholesterol ratio: the role of the laboratory as an indicator of insulin resistance
Salinas, K. A. S., & Pérez, E. A. G. (2024) · Salud Ciencia y Tecnología · doi:10.56294/saludcyt2024720 · Cited by 2
Duan, S., Chen, M., Chen, J., Shao, Y., Jin, X., Wang, C., Feng, P., Teng, X., & Yu, Z. (2025) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002998 · Cited by 2
Fu, C., Gong, Y., Gao, X., Li, Y., Wang, G., Han, B., Liu, S., Zhang, H., He, D., Wang, F., et al. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04130-4 · Cited by 1
Research Progress on the Treatment of Non-Alcoholic Fatty Liver Disease with Mediterranean Diet
王, 梓. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1551598 · Cited by 1
Is there a link between obesity phenotype and thyroid diseases? A mini-review of current concepts
Milewska-Kobos, E. M., Szczepanek‐Parulska, E., & Ruchała, M. A. (2023) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.2478/ahem-2023-0015 · Cited by 1
PLAKIDA, A. L., Юшковська, О., & Sierpińska, L. E. (2026) · World Journal of Hepatology · doi:10.4254/wjh.v18.i3.113284 · Cited by 1
Li, X., Zhou, G., Sun, C., She, R., Feng, W., Fu, X., Wu, S., Li, D., Pan, L., Liu, X., et al. (2026) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2026.110377 · Cited by 1
Association between perceived stress and MAFLD partially mediated by smoking and drinking
Gong, Y., Wang, S., Jiang, J., Zeng, Q., Wang, W., Zheng, Y., & Lv, W. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1569992 · Cited by 1
Role of Micronutrients in MAFLD
Pršo, A.-M. L., & Krznarić, Ž. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1008349 · Cited by 1
Biya, T., Sanusi, H. D., & Aman, A. M. (2026) · Journal of the ASEAN Federation of Endocrine Societies · doi:10.15605/jafes.041.01.5159 · Cited by 1
Zanuzo, K., Nishiyama, M. F., Koehnlein, E. A., & Grassiolli, S. (2025) · Pathophysiology · doi:10.3390/pathophysiology32040064 · Cited by 1
Diabetes Treatment and Prevention Using Herbal Medicine
Yusuf, B. O., Abdulsalam, R. A., & Sabiu, S. (2024) · Reference series in phytochemistry · doi:10.1007/978-3-031-43199-9_43 · Cited by 1
Yang, J., Li, X., & Qi, F. (2026) · BMC Gastroenterology · doi:10.1186/s12876-026-04799-1 · Cited by 1
Etiopatogenia/fisiopatología de la enfermedad del hígado graso no alcohólica (NAFLD)
Quintero, M. A. R., & Pérez, J. N. (2023) · Diabetes práctica · doi:10.52102/diabet/pract.esteatosis.art2 · Cited by 1
Dimova, R. B., Chakarova, N. Y., Serdarova, M. S., Marinova, C., Popov, D., Prato, S. D., & Tankova, T. I. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2024-004542 · Cited by 1
Insulin resistance as potential mediator linking ApoB/ApoA1 to MAFLD, but not inflammation
Yang, M., Liu, X., Li, Q., Liu, J., & Wang, B. (2025) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188251378318 · Cited by 1
Liu, W., Li, X., Hu, C., Zhang, H., Wu, Y., & Hu, Z. (2026) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-026-05656-3 · Cited by 1
Impact of Metabolic and Bariatric Surgery on Liver Diseases: Current Evidence
Agarwal, L., Chekuri, R., Singla, V., Kumar, A., Shalimar, S., & Aggarwal, S. (2022) · Journal of Bariatric Surgery · doi:10.4103/jbs.jbs_9_22 · Cited by 1
Luo, J., Jin, X., Cui, M., He, H., Liao, J., Wen, W., Li, W., & Cao, Y. (2026) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2026.107067 · Cited by 1
Features of molecular mechanisms of insulin resistance pathogenesis in various tissues in obesity
Kuzmenko, D. I., Klimenteva, T. K., Самойлова, Ю. Г., Denisov, N. S., & Матвеева, М. В. (2023) · Obesity and metabolism · doi:10.14341/omet12839 · Cited by 1
Xiaoran, W. A. N. G., Song, Y., Zhao, W., Liu, Y., Fu, Y., Zhang, Y., Zhao, Q., Miao, M., Zhao, W., Wang, X., et al. (2026) · npj Science of Food · doi:10.1038/s41538-026-00815-6 · Cited by 1
Microbiota and fatty liver disease: Potential candidate for therapeutic intervention
Eslami, M., Naderian, R., Tarahomi, M., Babaeizad, A., Amini, P., & Pouya, P. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27370-4.00026-3 · Cited by 1
Mani, V., Chandrashekar, S., Jayapal, J., Rajapandian, N., & Nisha, K. (2023) · Journal Of Advanced Zoology · doi:10.17762/jaz.v44i4.1638 · Cited by 1
Chen, K., Nong, Y., Liu, Y., & Ye, Z. (2026) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s575306 · Cited by 1
Decoding MASLD’s Pathophysiology
Abenavoli, L., & Scarlata, G. G. M. (2024) · Springer eBooks · doi:10.1007/978-981-97-9519-2_3 · Cited by 1
Wang, F., Mi, J., Bai, X., Ruan, G., Zhang, Y., & Yu, K. (2022) · Research Square · doi:10.21203/rs.3.rs-1751879/v2 · Cited by 1
GRg1 Ameliorates Insulin Resistance Through Activation of the PI3K/AKT/GSK-3β Pathway in HepG2 Cells
Shen, X., Jin, Y., Chen, Y., & Yang, H. (2023) · Pharmacognosy Magazine · doi:10.1177/09731296231198284 · Cited by 1
Effectiveness of dietary modifications in reversing damage induced by high-fat diet in rats
Jiménez‐García, M., Quetglas‐Llabrés, M. M., Valdés, S. C. E., Ribas‐Taberner, M. D. M., Gomila, A., Moranta, D., & Tejada, S. (2026) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-026-01205-y · Cited by 1
Liu, X., Ma, S., Li, J., Song, M., Li, Y., Qi, Y., Liu, F., Fang, Z., & Zheng, R. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf032 · Cited by 1
Kubacka, M., Nowak, B., Zadrożna, M., Szafarz, M., Latacz, G., Marona, H., Sapa, J., Mogilski, S., Bednarski, M., & Kotańska, M. (2023) · Metabolites · doi:10.3390/metabo13111130 · Cited by 1
Pan, X., Chen, S., Li, Y., Wang, R., Gong, Y., Huang, X., Li, S., & Liu, N. (2026) · Fish Physiology and Biochemistry · doi:10.1007/s10695-026-01718-9 · Cited by 1
Enzyme‐Activated MRI for In Vivo Glucose Imaging via a Biodegradable Chromium Nanoprobe
Xu, Y., Yang, W., Yun, Y., Wang, H., Wu, Z., Yu, Y., & Zhang, B. (2026) · Advanced Science · doi:10.1002/advs.74861 · Cited by 1
LncRNA Snhg3 Aggravates Hepatic Steatosis via PPARγ SignalingPreprint
Xie, X., Gao, M., Zhao, W. G., Li, C., Zhang, W., Yang, J., Zhang, Y., Chen, E., Guo, Y., Guo, Z., et al. (2024) · eLife · doi:10.7554/elife.96988.2 · Cited by 1
Yang, Q.-Q., Qian, Q.-H., Zhang, W., Song, Y.-P., Huang, Q.-Y., Lu, X., Wang, T., Huang, Y., & Xu, D. (2026) · Environment & Health · doi:10.1021/envhealth.5c00540 · Cited by 1
Gyoutoku, N., Inoguchi, Y., Rikitake, J., Demiya, M., Gobaru, M., Nagayama, A., Iwata, S., Hasuzawa, N., Nakayama, H., Ashida, K., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0335888 · Cited by 1
Baokbah, T. A. S. (2023) · International Journal of Morphology · doi:10.4067/s0717-95022023000601887 · Cited by 1
Non-alcoholic fatty liver disease: a current challenge of interdisciplinary research
Biryukova, E. V. (2024) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2024-159 · Cited by 1
Chen, Q., Hu, Q., Zhang, F., Lu, W., Zheng, Y., & Qiao, F. (2025) · Hereditas · doi:10.1186/s41065-025-00427-2 · Cited by 1
Hameed, S. M., & Abdulrahman, S. J. (2025) · International Journal of Life Science Research Archive · doi:10.53771/ijlsra.2025.8.2.0031 · Cited by 1
Asprosin in nonalcoholic fatty liver disease and hypothyroidism: a case-control study
Aboul-Seoud, M. A.-L., Ghitany, M. K., Sharaki, O. A., Abdul-Aziz, A. A., & Shater, M. S. S. (2024) · Alexandria Journal of Medicine · doi:10.1080/20905068.2024.2381153 · Cited by 1
Wang, Y., Chen, Y., Wang, Y., Chen, L., Yin, M., Xiao, X., Huang, J., Kuang, J., & Li, Y. (2026) · PubMed Central · doi:10.11817/j.issn.1672-7347.2025.250010 · Cited by 1
Leonardi, B. F. (2021) · theses.fr (ABES) · doi:10.70675/00f56ed9z2249z4285zbb57z3aa47bb72094 · Cited by 1
Suhaili, N. A., Lim, Y. C., Lim, M. A., Lim, L. H., Khan, M. M., & Siddique, M. M. (2025) · ASEAN Journal on Science and Technology for Development · doi:10.61931/2224-9028.1633 · Cited by 1
Wu, S., Chen, N., Wu, M., Wang, Y., Huang, Z., Zhang, J., Li, J., Xu, D., Guan, L., & Ge, J. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-099668 · Cited by 1
Liang, H., & Wei, Y. (2025) · PLoS ONE · doi:10.1371/journal.pone.0328576 · Cited by 1
Xie, Y. (2023) · Academic Journal of Medicine & Health Sciences · doi:10.25236/ajmhs.2023.040909 · Cited by 1
Cai, H., Yang, C., & Gao, P. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i15.104528 · Cited by 1
Rico‐Chazarra, S., García-Melgares, C., Ros‐Madrid, I., Martínez‐Sánchez, M. A., Sánchez‐Alcoholado, L., Oliva‐Bolarín, A., Fernández-Ruiz, V. E., Ferrer‐Gómez, M., Ruiz‐Alcaraz, A. J., Martínez, C. M., et al. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119687
PYY 3–36 potentiates semaglutide-mediated mitochondrial modulation in MASLD
Geiger, N., Nickel, A. G., Kohlhaas, M., Federspiel, J. M., Gerner, J., Landthaler, A.-N., Kloock, S., Bischler, T., Arampatzi, P., Matz, M., et al. (2026) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00036.2026
Zhao, X. Y., Hong, Y., Bian, S., Jiao, H., Zhong, X., & Ni, W. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1839364
屈, 飏. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1381788
Swierczek, D., Dreger, M., Jatkowski, J., Kancerek, J., Drozdzowska, B., & Wojnicz, R. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177825
Kruszewski, A., Dąbrowska, A., Przybysz, P., Kucharska, M., Szyszka, M., Paduszyńska, N., & Błaszczak, K. (2024) · Quality in Sport · doi:10.12775/qs.2024.17.53023
Yin, L., Hu, Y., Hu, X., Huang, X., Chen, Y., & Zhang, Y. (2024) · Twin Research and Human Genetics · doi:10.1017/thg.2024.16
Lu, J., Li, J., Yin, P., Huang, N., & Sun, R. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.122376
Tan, J., Jianhua, H., Zhang, H., & Wu, S. (2026) · Foods · doi:10.3390/foods15030437
Juárez‐Fernández, M. (2023) · Buleria (Universidad de León) · doi:10.18002/10612/17419
Liu, H., & Xin, Y. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1833858
Marcos, P. J. T., López‐González, Á. A., Rifá, E. M.-A., Paublini, H., Sánchez, C. M., López, P. J. T., & Ramírez‐Manent, J. I. (2025) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2025.102514
Lu, Z., Hu, Y., Zong, D., & Yue, B. (2025) · Research Square · doi:10.21203/rs.3.rs-7620270/v1
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4473-0
la Torre-Espinosa, Z. Y. D., Valenzuela, M. J. C., Leyva-Morales, J. B., Douriet, L. U. B., Delcid, P. A. R., & Espinosa, R. R. (2026) · Revista Bio Ciencias · doi:10.15741/revbio.13.e2157
Nanomedicines to alleviate hepatic metabolic disorders
Baidya, A., Ghosh, I., Sar, S., Banerjee, T., Kumar, A., Saha, S., Chaki, R., Halder, A. K., & Ghosh, N. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-28942-2.00007-7
Metadata
- Authors
- Sakurai, Y., Kubota, N., Yamauchi, T., & Kadowaki, T.
- Affiliations
- The University of Tokyo (JP)
- National Institute of Biomedical Innovation, Health and Nutrition (JP)
- Toranomon Hospital (JP)
- Corresponding author
- Kubota, Naoto
- Kadowaki, Takashi
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-04-16
- Volume
- 22
- Issue
- 8
- Pages
- 4156
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8072900
- OpenAlex
- W3155254720
- Cited by
- 448
- References
- 195
- Citations by year
- 2026: 72 · 2025: 129 · 2024: 125 · 2023: 80 · 2022: 37 · 2021: 5
- FWCI
- 9.50
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Japan Society for the Promotion of Science (19K17977)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- non-alcoholic fatty liver disease, insulin resistance, hepatic insulin resistance, hepatic steatosis, liver fibrosis, de novo lipogenesis, gut microbiota, metabolic syndrome, obesity, type 2 diabetes, endoplasmic reticulum stress, liver inflammation, hepatocarcinogenesis
- MeSH terms
- Animals, Humans, Insulin, Signal Transduction, Metabolic Syndrome, Lipogenesis, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.